NCT04123470 - A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

July 30, 2023

Study Completion Date

July 30, 2023

Conditions

Malignant Melanoma

Interventions

GENETIC

delolimogene mupadenorepvec

LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL

BIOLOGICAL

atezolizumab

Atezolizumab is an anti-PD-L1 antibody

Trial Locations (3)

Uppsala University Hospital, Uppsala

Baylor St Luke's Medical Center, Houston

Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles